NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES (NIJSES)

Volume 7 Issue 2 Page 61-65, 2026

ONLINE ISSN:2992-5819 PRINT ISSN:2992-6149

Open Access

https://doi.org/10.59298/NIJSES/2026/72.6165

Nanotechnology-Driven Modulation of Lipid and Glucose Dysregulation in Obesity and Diabetes

Winniefred Nankya

Department of Clinical Pharmacy Kampala International University Uganda
Email:winniefred.nankya@studwc.kiu.ac.ug

ABSTRACT

Obesity and type 2 diabetes (T2D) are major contributors to the global burden of chronic disease, with both conditions sharing common underlying mechanisms, including lipid and glucose dysregulation. Obesity, especially visceral fat accumulation, leads to insulin resistance, inflammation, and disturbed lipid metabolism, creating an environment conducive to the development of T2D. Current therapeutic strategies predominantly focus on managing blood glucose levels or reducing body weight, yet they often fail to address the root causes of lipid and glucose dysregulation. Nanotechnology presents a novel approach to treating these conditions by enabling the precise delivery of therapeutic agents that can modulate lipid metabolism and improve glucose homeostasis. By leveraging the unique properties of nanoparticles, nanocarriers can target adipose tissue, liver, muscle, and pancreas with high specificity. Nanotechnology-driven strategies can promote insulin sensitivity, reduce lipid accumulation, and restore metabolic balance, potentially offering more effective treatments for obesity-related metabolic disorders. This review explores the mechanisms by which nanotechnology can modulate lipid and glucose dysregulation in obesity and T2D. It also examines the potential benefits and challenges of translating these nanomedicines into clinical practice, highlighting the exciting opportunities for improving therapeutic outcomes in these complex diseases.

Keywords: Nanotechnology, Obesity, Type 2 Diabetes, Lipid Metabolism, Glucose Dysregulation.

INTRODUCTION

Obesity and type 2 diabetes (T2D) have become significant public health concerns worldwide, with their prevalence steadily increasing[1–4]. Both of these conditions are closely related and share common pathological mechanisms, particularly lipid and glucose dysregulation. Obesity, especially the accumulation of visceral fat, disrupts normal metabolic processes and is a major contributor to the development of insulin resistance, a central feature of T2D. As insulin resistance worsens, glucose homeostasis becomes impaired, leading to hyperglycemia and the eventual progression of diabetes[5–8]. In addition to glucose dysregulation, obesity results in disturbed lipid metabolism, which further exacerbates insulin resistance and contributes to the development of T2D-related complications[9–11].

Lipid dysregulation in obesity leads to increased circulating free fatty acids (FFAs), which are toxic to tissues such as the liver and skeletal muscle, impairing insulin sensitivity. The liver, in particular, becomes a central player in this process, accumulating fat and further exacerbating the insulin resistance seen in obesity[4, 10, 12, 13]. This creates a vicious cycle where metabolic disturbances in lipid and glucose metabolism perpetuate each other, leading to further dysfunction in the adipose tissue, liver, pancreas, and muscle[14].

While current therapeutic strategies for obesity and T2D, such as lifestyle changes, oral medications, and insulin therapy, aim to control blood glucose levels or reduce body weight, they often fail to target the underlying causes of lipid and glucose dysregulation. As a result, there is a pressing need for more effective, targeted therapies that can modulate lipid metabolism and restore glucose homeostasis at the molecular level[15, 16]. Nanotechnology, with its ability to precisely target tissues, encapsulate drugs, and regulate release kinetics, provides a powerful platform for addressing these metabolic disturbances in obesity and diabetes.

Nanotechnology has already shown promising potential in drug delivery systems, biomolecular modulation, and the development of novel therapeutics for obesity and T2D[17–19]. Nanoparticles can be engineered to deliver insulin-sensitizing agents, anti-inflammatory drugs, or lipid-regulating compounds directly to affected tissues such as adipose tissue, liver, and muscle[20, 21]. These targeted approaches allow for more precise interventions that address the root causes of metabolic dysfunction, offering the potential for better therapeutic outcomes. This review will explore how nanotechnology-driven strategies can modulate lipid and glucose dysregulation in obesity and T2D. We will examine the mechanisms by which nanomedicine can enhance insulin sensitivity, regulate lipid metabolism, and restore metabolic balance. Additionally, the review will address the challenges of translating these promising nanotherapeutics from the laboratory to clinical settings, as well as the translational opportunities that could revolutionize the management of obesity-related metabolic disorders.

2. Mechanisms of Lipid Dysregulation in Obesity and Diabetes

Lipid dysregulation is one of the key metabolic abnormalities in both obesity and type 2 diabetes (T2D), contributing significantly to the development of insulin resistance and the progression of diabetes[22]. In obesity, especially visceral adiposity, adipocytes become enlarged and release an altered profile of bioactive molecules known as adipokines, including pro-inflammatory cytokines such as TNF-α, IL-6, and resistin. These cytokines promote insulin resistance by interfering with insulin signaling pathways in insulin-sensitive tissues like adipose tissue, muscle, and liver. Additionally, the dysfunction of adipose tissue leads to the excessive release of free fatty acids (FFAs) into circulation, further exacerbating insulin resistance[23, 24].

Excessive accumulation of FFAs in non-adipose tissues, particularly the liver and skeletal muscle, is known as ectopic fat deposition. In the liver, the accumulation of FFAs leads to the development of non-alcoholic fatty liver disease (NAFLD), which further exacerbates insulin resistance. Ectopic fat in muscle impairs glucose uptake and utilization, making it more difficult for the body to maintain normal blood glucose levels[25, 26].

In addition to FFAs, dysregulated lipid metabolism in obesity also involves increased production of triglycerides and alterations in lipoprotein metabolism. These changes contribute to the development of dyslipidemia, which is characterized by elevated levels of triglycerides and low levels of high-density lipoprotein (HDL) cholesterol, both of which are common features of T2D. This altered lipid profile further exacerbates insulin resistance and accelerates the progression of diabetes[21]. Understanding the mechanisms of lipid dysregulation in obesity and diabetes is essential for developing effective therapeutic strategies. Nanotechnology offers a potential solution by providing a means of targeting the underlying molecular pathways involved in lipid metabolism. By delivering lipid-regulating agents to specific tissues, nanomedicine can reduce lipid accumulation, restore normal lipid profiles, and improve insulin sensitivity, thereby addressing one of the primary causes of insulin resistance in these diseases.

3. Nanotechnology-Driven Modulation of Lipid Metabolism

Nanotechnology-driven interventions have the potential to revolutionize the treatment of lipid dysregulation in obesity and diabetes by offering more precise and effective modulation of lipid metabolism[27]. One of the primary goals of nanomedicine in this context is to reduce excessive fat accumulation in adipose tissue and non-adipose tissues, such as the liver and muscle, which contribute to insulin resistance.

Nanoparticles can be engineered to deliver small molecules or RNA-based therapies that target key enzymes involved in lipid metabolism. For example, nanoparticles can deliver inhibitors of acetyl-CoA carboxylase (ACC) or sterol regulatory element-binding proteins (SREBPs), which are critical regulators of fatty acid synthesis. By inhibiting these enzymes, nanocarriers can reduce the production of triglycerides and the accumulation of fat in tissues such as the liver and muscle[28–30]. Additionally, nanoparticles can be used to deliver agents that promote fatty acid oxidation and lipolysis, which help break down stored fat and improve insulin sensitivity. Nanocarriers can be designed to target adipose tissue and deliver compounds that activate AMP-activated protein kinase (AMPK), a key regulator of lipid metabolism. By promoting fatty acid oxidation, AMPK activation can reduce lipid accumulation in peripheral tissues, improving insulin sensitivity and glucose metabolism[31, 32]. Another promising application of nanomedicine in lipid metabolism modulation is the use of nanoparticles to deliver lipid-lowering agents, such as statins or fibrates, directly to the liver. These agents can help normalize cholesterol levels, reduce triglyceride accumulation, and improve overall lipid profiles, further enhancing insulin sensitivity and reducing the risk of cardiovascular complications associated with obesity and T2D.

4. Nanotechnology for Targeting Glucose Dysregulation in Obesity and Diabetes

The regulation of glucose metabolism is a cornerstone in the management of obesity and type 2 diabetes (T2D). In obesity-related insulin resistance, the inability of tissues to respond to insulin leads to impaired glucose uptake and utilization, resulting in elevated blood glucose levels. Nanotechnology offers an innovative approach to improving glucose regulation by targeting key tissues involved in glucose metabolism, such as the liver, muscle, and pancreas[33].

Nanoparticles can be designed to deliver insulin-sensitizing agents, such as metformin or thiazolidinediones (TZDs), directly to insulin-resistant tissues. By targeting these agents to the liver or muscle, where insulin resistance is most pronounced, nanomedicine can improve insulin signaling, enhance glucose uptake, and reduce hyperglycemia[34]. Additionally, nanocarriers can be engineered to deliver glucagon-like peptide-1 (GLP-1)

agonists, which stimulate insulin secretion from pancreatic β-cells and improve insulin sensitivity in peripheral tissues.

Another strategy for modulating glucose metabolism is to use nanoparticles to deliver small molecules or RNA-based therapies that target key enzymes involved in glucose production and utilization, such as glucokinase or AMP-activated protein kinase (AMPK)[35]. These enzymes play critical roles in maintaining normal glucose homeostasis, and their modulation by nanotechnology can help restore normal glucose metabolism in insulin-resistant tissues.

By targeting glucose dysregulation at the molecular level, nanomedicine offers the potential for more precise and effective treatments for obesity-related T2D, which could provide better control over blood glucose levels and prevent the progression of the disease[35].

5. Challenges in Translating Nanotechnology to Clinical Practice

Nanotechnology offers innovative solutions for modulating lipid and glucose dysregulation in obesity and type 2 diabetes (T2D), yet its transition from experimental research to routine clinical application is accompanied by substantial challenges. These barriers span safety concerns, biological complexity, patient heterogeneity, and manufacturing limitations, all of which must be addressed to ensure the successful clinical translation of nanomedicine-based therapies.

Safety and Biocompatibility

Safety and biocompatibility remain the most critical challenges in the clinical deployment of nanomedicines. Nanoparticles possess unique physicochemical properties, including high surface area, enhanced reactivity, and the ability to cross biological barriers, which can result in unintended interactions with tissues and organs[36]. Following systemic administration, nanoparticles may accumulate in the liver, kidneys, spleen, and lungs, raising concerns regarding long-term toxicity, oxidative stress, immune activation, and chronic inflammation. These risks are particularly relevant for obesity and T2D, which often require long-term or lifelong therapeutic interventions.

The long-term fate of nanoparticles within the human body remains incompletely understood. Factors such as particle size, surface charge, composition, and degradability significantly influence biodistribution and clearance pathways[37]. Non-biodegradable or slowly degradable nanomaterials may persist in tissues, increasing the risk of cumulative toxicity. Therefore, comprehensive toxicological evaluations, including chronic exposure, reproductive toxicity, immunogenicity, and carcinogenicity studies, are essential prior to clinical approval. The development of biodegradable, bioinspired, and naturally derived nanomaterials may help mitigate these safety concerns and improve patient acceptance[37].

Personalized Medicine and Patient Variability

Obesity and T2D are highly heterogeneous diseases shaped by complex interactions between genetic predisposition, environmental factors, lifestyle choices, and metabolic status. This variability presents a significant challenge to the development of universally effective nanotherapeutics[38]. Differences in disease stage, adipose tissue distribution, inflammatory burden, and insulin sensitivity can influence nanoparticle biodistribution, cellular uptake, and therapeutic response[38].

Personalized nanomedicine approaches are therefore likely to be necessary to optimize clinical outcomes. Tailoring nanoparticle design, targeting ligands, drug payloads, and release kinetics to individual patient profiles could enhance efficacy while minimizing adverse effects[39]. Advances in genomics, metabolomics, and biomarker discovery may enable patient stratification and guide personalized treatment strategies[40]. However, implementing personalized nanomedicine in clinical practice will require robust diagnostic tools, scalable customization processes, and integration into existing healthcare systems.

Manufacturing and Scalability

Manufacturing scalability and reproducibility represent additional hurdles in translating nanomedicine to the clinic. Many nanoparticle formulations involve complex synthesis methods that are difficult to reproduce consistently at large scale. Variability in particle size, surface properties, and drug-loading efficiency can significantly affect therapeutic performance and safety.

To achieve widespread clinical adoption, nanomedicines must be produced using cost-effective, reproducible, and Good Manufacturing Practice (GMP)-compliant processes. Standardization of manufacturing protocols, quality control measures, and stability testing will be essential to ensure batch-to-batch consistency. Overcoming these manufacturing challenges is critical for reducing costs and enabling global access to nanotechnology-based therapies.

6. Future Perspectives and Translational Opportunities

Despite these challenges, the future of nanomedicine in the management of obesity and T2D is highly promising. Rapid advances in nanotechnology, materials science, and systems biology are driving the development of next-generation nanotherapeutics with improved precision, safety, and therapeutic efficacy.

One of the most exciting developments is the emergence of smart nanocarriers capable of responding to disease-specific environmental cues, such as pH changes, oxidative stress, inflammatory mediators, or glucose levels[41]. These stimuli-responsive systems allow controlled, on-demand drug release at the site of pathology, minimizing systemic exposure and reducing side effects. In metabolic diseases, smart nanocarriers could

dynamically adjust therapeutic delivery in response to metabolic fluctuations, closely mimicking physiological regulatory mechanisms.

Another important translational opportunity lies in the integration of nanomedicine with advanced therapeutic modalities, including gene therapy, RNA-based interventions, and immunomodulation[42]. Nanoparticles can serve as safe and efficient delivery vehicles for nucleic acids, enabling targeted regulation of genes involved in insulin signaling, lipid metabolism, inflammation, and β-cell function. Such combinatorial approaches may provide more durable and disease-modifying effects compared with conventional monotherapies.

The development of multifunctional and combination nanotherapies further expands the translational potential of nanomedicine. By co-delivering insulin sensitizers, anti-inflammatory agents, and β-cell–protective compounds within a single platform, nanotechnology can address multiple pathogenic pathways simultaneously[43]. This holistic approach is particularly well suited to the complex and interconnected nature of obesity and T2D.

As regulatory frameworks evolve and interdisciplinary collaborations strengthen, the path toward clinical translation is becoming increasingly feasible. Continued investment in preclinical validation, standardized evaluation methods, and translational research will be essential to bridge the gap between laboratory innovation and clinical application.

CONCLUSION

Nanotechnology represents a transformative approach to the treatment of obesity and type 2 diabetes by enabling targeted modulation of lipid and glucose dysregulation at the molecular and cellular levels. While challenges related to safety, patient variability, and manufacturing scalability remain, ongoing advances in smart nanocarriers, personalized medicine, and multifunctional delivery systems are rapidly addressing these barriers. With continued interdisciplinary research and thoughtful regulatory development, nanomedicine has the potential to revolutionize metabolic disease management by offering safer, more precise, and more effective therapeutic strategies that target the root causes of obesity and T2D rather than merely alleviating symptoms.

REFERENCES

1. Aloo, S.O., Barathikannan, K., Oh, D.-H.: Polyphenol-rich fermented hempseed ethanol extracts improve obesity, oxidative stress, and neural health in high-glucose diet-induced *Caenorhabditis elegans*. Food Chem. X. 21, 101233 (2024). https://doi.org/10.1016/j.fochx.2024.101233
2. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obes. Med. 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
3. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., Agwupuye, E.I., Obeten, U.N., Maitra, S., Subramaniyan, V., Wong, L.S., Aljarba, N.H., Kumarasamy, V.: Tetracarpidium conophorum nuts (African walnuts) up-regulated adiponectin and PPAR-γ expressions with reciprocal suppression of TNF-α gene in obesity. J. Cell. Mol. Med. 28, e70086 (2024). https://doi.org/10.1111/jcmm.70086
4. David-Oku, E., De Campos, O.C., Udeozor, P.A., Nfona, S.O., Lawal, B.: Modulation of Lipogenesis by Tetracarpidium conophorum Nuts via SREBP-1/ACCA-1/FASN Inhibition in Monosodium-Glutamate-Induced Obesity in Rats. Nat. Prod. Commun. 20, 1934578X251344035 (2025). https://doi.org/10.1177/1934578X251344035
5. Ahmed, B., Sultana, R., Greene, M.W.: Adipose tissue and insulin resistance in obese. Biomed. Pharmacother. 137, 111315 (2021). https://doi.org/10.1016/j.biopha.2021.111315
6. Bansal, S.K., Bansal, M.B.: Pathogenesis of MASLD and MASH – role of insulin resistance and lipotoxicity. Aliment. Pharmacol. Ther. 59, S10–S22 (2024). https://doi.org/10.1111/apt.17930
7. Bensussen, A., Torres-Magallanes, J.A., Roces De Álvarez-Buylla, E.: Molecular tracking of insulin resistance and inflammation development on visceral adipose tissue. Front. Immunol. 14, 1014778 (2023). https://doi.org/10.3389/fimmu.2023.1014778
8. Elkanawati, R.Y., Sumiwi, S.A., Levita, J.: Impact of Lipids on Insulin Resistance: Insights from Human and Animal Studies. Drug Des. Devel. Ther. 18, 3337–3360 (2024). https://doi.org/10.2147/DDDT.S468147
9. Rabiee, A., Hossain, M.A., Poojari, A.: Adipose Tissue Insulin Resistance: A Key Driver of Metabolic Syndrome Pathogenesis. Biomedicines. 13, 2376 (2025). https://doi.org/10.3390/biomedicines13102376
10. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
11. Suren Garg, S., Kushwaha, K., Dubey, R., Gupta, J.: Association between obesity, inflammation and insulin resistance: Insights into signaling pathways and therapeutic interventions. Diabetes Res. Clin. Pract. 200, 110691 (2023). https://doi.org/10.1016/j.diabres.2023.110691
12. Panic, A., Stanimirovic, J., Sudar-Milovanovic, E., Isenovic, E.R.: Oxidative stress in obesity and insulin resistance. Explor. Med. 3, 58–70 (2022). https://doi.org/10.37349/emed.2022.00074
13. Guerreiro, V.A., Carvalho, D., Freitas, P.: Obesity, Adipose Tissue, and Inflammation Answered in Questions. J. Obes. 2022, 2252516 (2022). https://doi.org/10.1155/2022/2252516

14. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
15. Allocca, S., Monda, A., Messina, A., Casillo, M., Sapuppo, W., Monda, V., Polito, R., Maio, G.D., Monda, M., Marra, M.L.: Endocrine and Metabolic Mechanisms Linking Obesity to Type 2 Diabetes: Implications for Targeted Therapy. Healthcare. 13, (2025). https://doi.org/10.3390/healthcare13121437
16. Nurkolis, F., Harbuwono, D.S., Taslim, N.A., Soegondo, S., Suastika, K., Sparringa, R.A., Mustika, A., Syam, A.F., Santini, A., Holly, J.M.P., Bhunia, A.K., Tjandrawinata, R.R.: New insight on dietary strategies to increase insulin sensitivity and reduce diabetes prevalence: an expert perspective and recommendation. Discov. Food. 5, 136 (2025). https://doi.org/10.1007/s44187-025-00422-6
17. Omang, W.A., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Targeting CD44-Hyaluronic Acid Signalling in Obesity Treatment: Insights from Small Molecules and Nanobioconjugates. Nutr. Metab. Insights. 19, 11786388251408961 (2026). https://doi.org/10.1177/11786388251408961
18. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int. J. Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250
19. Xu, M., Zhang, X., Yu, X., Ma, C., Li, X., Chen, G., Yuan, G., Lin, S., Cui, R.: Epigenetic and metabolic reprogramming via nanotechnology: a synergistic approach to cancer vaccination in lung tumors. Front. Genet. 16, 1666561 (2025). https://doi.org/10.3389/fgene.2025.1666561
20. Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., Li, T.: Signaling pathways in obesity: mechanisms and therapeutic interventions. Signal Transduct. Target. Ther. 7, 298 (2022). https://doi.org/10.1038/s41392-022-01149-x
21. Boles, A., Kandimalla, R., Reddy, P.H.: Dynamics of diabetes and obesity: Epidemiological perspective. Biochim. Biophys. Acta BBA - Mol. Basis Dis. 1863, 1026–1036 (2017). https://doi.org/10.1016/j.bbadis.2017.01.016
22. Wondmkun, Y.T.: Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. Diabetes Metab. Syndr. Obes. Targets Ther. 13, 3611–3616 (2020). https://doi.org/10.2147/DMSO.S275898
23. Jin, X., Qiu, T., Li, L., Yu, R., Chen, X., Li, C., Proud, C.G., Jiang, T.: Pathophysiology of obesity and its associated diseases. Acta Pharm. Sin. B. 13, 2403–2424 (2023). https://doi.org/10.1016/j.apsb.2023.01.012
24. Alum, E.U., Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A., Alum, B.N.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
25. Snel, M., Jonker, J.T., Schoones, J., Lamb, H., de Roos, A., Pijl, H., Smit, J.W.A., Meinders, A.E., Jazet, I.M.: Ectopic Fat and Insulin Resistance: Pathophysiology and Effect of Diet and Lifestyle Interventions. Int. J. Endocrinol. 2012, 983814 (2012). https://doi.org/10.1155/2012/983814
26. Luo, J., Wang, Y., Mao, J., Yuan, Y., Luo, P., Wang, G., Zhou, S.: Features, functions, and associated diseases of visceral and ectopic fat: a comprehensive review. Obesity. 33, 825–838 (2025). https://doi.org/10.1002/oby.24239
27. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
28. Anselmo, A.C., Mitragotri, S.: A Review of Clinical Translation of Inorganic Nanoparticles. AAPS J. 17, 1041–1054 (2015). https://doi.org/10.1208/s12248-015-9780-2
29. Bigaj-Józefowska, M.J., Coy, E., Załęski, K., Zalewski, T., Grabowska, M., Jaskot, K., Perrigue, P., Mrówczyński, R., Grześkowiak, B.F.: Biomimetic theranostic nanoparticles for effective anticancer therapy and MRI imaging. J. Photochem. Photobiol. B. 249, 112813 (2023). https://doi.org/10.1016/j.jphotobiol.2023.112813
30. Huang, X., He, T., Liang, X., Xiang, Z., Liu, C., Zhou, S., Luo, R., Bai, L., Kou, X., Li, X., Wu, R., Gou, X., Wu, X., Huang, D., Fu, W., Li, Y., Chen, R., Xu, N., Wang, Y., Le, H., Chen, T., Xu, Y., Tang, Y., Gong, C.: Advances and applications of nanoparticles in cancer therapy. MedComm – Oncol. 3, e67 (2024). https://doi.org/10.1002/mog2.67
31. Long, Q., Liu, Z., Shao, Q., Shi, H., Huang, S., Jiang, C., Qian, B., Zhong, Y., He, X., Xiang, X., Yang, Y., Li, B., Yan, X., Zhao, Q., Wei, X., Santos, H.A., Ye, X.: Autologous Skin Fibroblast-Based PLGA Nanoparticles for Treating Multiorgan Fibrosis. Adv. Sci. 9, 2200856 (2022). https://doi.org/10.1002/advs.202200856
32. Koushki, K., Biswal, P., Vijay, G.V., Sadeghi, M., Dehnavi, S., Tra, N.T., Samala, S.K., Taba, M.Y., Vasan, A.B., Han, E., Mackeyev, Y., Krishnan, S.: Immunomodulatory Effects of Gold Nanoparticles: Impacts on Immune Cells and Mechanisms of Action. Nanomaterials. 15, (2025). https://doi.org/10.3390/nano15151201

33. Sarkhel, S., Shuvo, S.M., Ansari, M.A., Mondal, S., Kapat, P., Ghosh, A., Sarkar, T., Biswas, R., Atanase, L.I., Carauleanu, A.: Nanotechnology-Based Approaches for the Management of Diabetes Mellitus: An Innovative Solution to Long-Lasting Challenges in Antidiabetic Drug Delivery. Pharmaceutics. 16, 1572 (2024). https://doi.org/10.3390/pharmaceutics16121572
34. Iqbal, N., Ambery, P., Logue, J., Mallappa, A., Sjöström, C.D.: Perspectives in weight control in diabetes – SGLT2 inhibitors and GLP-1–glucagon dual agonism. Diabetes Res. Clin. Pract. 199, 110669 (2023). https://doi.org/10.1016/j.diabres.2023.110669
35. Zhang, Y., Li, Q., Huang, Z., Li, B., Nice, E.C., Huang, C., Wei, L., Zou, B.: Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies. Cancers. 14, 4568 (2022). https://doi.org/10.3390/cancers14194568
36. Elmowafy, E.M., Tiboni, M., Soliman, M.E.: Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)/poly(lactic-co-glycolic acid) micro and nanoparticles. J. Pharm. Investig. 49, 347–380 (2019). https://doi.org/10.1007/s40005-019-00439-x
37. Yu, J., Dan, N., Eslami, S.M., Lu, X.: State of the Art of Silica Nanoparticles: An Overview on Biodistribution and Preclinical Toxicity Studies. AAPS J. 26, 35 (2024). https://doi.org/10.1208/s12248-024-00906-w
38. Pillon, N.J., Loos, R.J.F., Marshall, S.M., Zierath, J.R.: Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care. Cell. 184, 1530–1544 (2021). https://doi.org/10.1016/j.cell.2021.02.012
39. Kazi, R.N.A., Hasani, I.W., Khafaga, D.S.R., Kabba, S., Farhan, M., Aatif, M., Muteeb, G., Fahim, Y.A.: Nanomedicine: The Effective Role of Nanomaterials in Healthcare from Diagnosis to Therapy. Pharmaceutics. 17, 987 (2025). https://doi.org/10.3390/pharmaceutics17080987
40. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. Discov. Public Health. 22, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
41. Hossen, S., Hossain, M.K., Basher, M.K., Mia, M.N.H., Rahman, M.T., Uddin, M.J.: Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review. J. Adv. Res. 15, 1–18 (2018). https://doi.org/10.1016/j.jare.2018.06.005
42. Shahid, U.: Advances in RNA therapeutics: Classes, innovations and clinical applications. J. Precis. Med. Health Dis. 3, (2025). https://doi.org/10.1016/j.premed.2025.100016
43. Adekiya, T.A., Hudson, T., Bakare, O., Ameyaw, E.E., Adebayo, A., Olajubutu, O., Adesina, S.K.: PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer. Biomed. Pharmacother. 177, 117125 (2024). https://doi.org/10.1016/j.biopha.2024.117125

CITE AS: Winniefred Nankya (2026). Nanotechnology-Driven Modulation of Lipid and Glucose Dysregulation in Obesity and Diabetes. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES, 7(2):61-65.
https://doi.org/10.59298/NIJSES/2026/72.6165